Draft guideline on quality aspects of mRNA vaccines for veterinary use
Submitted by Anonymous (not verified) on 20 February 2026 - 12:00
Draft guideline on quality aspects of mRNA vaccines for veterinary use
PSUSA/00001307/202507
Submitted by Anonymous (not verified) on 20 February 2026 - 10:50
PSUSA/00001307/202507
Human medicines European public assessment report (EPAR): Palonosetron Accord, palonosetron, Date of authorisation: 26/05/2016, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 10:10
Human medicines European public assessment report (EPAR): Palonosetron Accord, palonosetron, Date of authorisation: 26/05/2016, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), seladelpar lysine dihydrate, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 9:40
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), seladelpar lysine dihydrate, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Date of authorisation: 23/06/2017, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 9:34
Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Date of authorisation: 23/06/2017, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Date of authorisation: 13/12/2011, Revision: 22, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 9:20
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Date of authorisation: 13/12/2011, Revision: 22, Status: Authorised
Risk management requirements for elemental impurities in veterinary medicinal products - Scientific guideline
Submitted by Anonymous (not verified) on 20 February 2026 - 8:26
Risk management requirements for elemental impurities in veterinary medicinal products - Scientific guideline
Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 19 February 2026 - 16:15
Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 19 February 2026 - 15:00
Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised
Submitted by Anonymous (not verified) on 19 February 2026 - 14:10
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised